I was standing in the Xyloph synthesis lab, watching the clarity of our latest batch hit ninety-nine percent. The light was perfect. The projections were even brighter. Then the report from the Brazil-Sector regulatory desk arrived. Oral agonists. Mass-market, once-a-day delivery systems hitting the markets faster than our biopolymer patents can pivot. The spectrum is shifting from high-margin specialized care to low-resolution mass saturation. Everyone sees a growth surge in the agonist sector. I see a spectrum being muddied by volume. When the brilliance of a monopoly is diluted by sheer scale, the light begins to fade. True clarity requires more than just market penetration. It requires owning the frequency.